Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
LABU
Upturn stock ratingUpturn stock rating

Direxion Daily S&P Biotech Bull 3X Shares (LABU)

Upturn stock ratingUpturn stock rating
$68.09
Last Close (24-hour delay)
Profit since last BUY12.84%
upturn advisory
Consider higher Upturn Star rating
BUY since 20 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

07/10/2025: LABU (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Analysis of Past Performance

Type ETF
Historic Profit -12.46%
Avg. Invested days 28
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
ETF Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 07/10/2025

Key Highlights

Volume (30-day avg) -
Beta 2.3
52 Weeks Range 32.42 - 151.80
Updated Date 06/29/2025
52 Weeks Range 32.42 - 151.80
Updated Date 06/29/2025

ai summary icon Upturn AI SWOT

Direxion Daily S&P Biotech Bull 3X Shares

stock logo

ETF Overview

overview logo Overview

The Direxion Daily S&P Biotech Bull 3X Shares (LABU) seeks daily investment results, before fees and expenses, of 300% of the performance of the S&P Biotechnology Select Industry Index. It offers leveraged exposure to the biotech sector, targeting short-term gains through magnified returns.

reliability logo Reputation and Reliability

Direxion is a well-known issuer of leveraged and inverse ETFs, recognized for its specialized investment products. The firm has a reasonable track record, but its leveraged products are known to be high-risk.

reliability logo Management Expertise

Direxion's management team has expertise in developing and managing complex investment strategies, specifically leveraged and inverse funds.

Investment Objective

overview logo Goal

To seek daily investment results, before fees and expenses, of 300% of the performance of the S&P Biotechnology Select Industry Index.

Investment Approach and Strategy

Strategy: The ETF employs a leveraged strategy, aiming to magnify the daily returns of the S&P Biotechnology Select Industry Index. This is achieved through derivatives and other leveraged instruments.

Composition The ETF primarily holds financial instruments (derivatives) designed to provide 3x leveraged exposure to the underlying index, with some allocation to equity to meet regulatory requirements. The composition changes daily based on the leverage target.

Market Position

Market Share: LABU has a significant market share among leveraged biotech ETFs, although its overall sector share is influenced by the size of non-leveraged biotech ETFs.

Total Net Assets (AUM): 653493727

Competitors

overview logo Key Competitors

  • ProShares Ultra Nasdaq Biotechnology (BIB)
  • ProShares UltraPro Nasdaq Biotechnology (UBIO)
  • iShares Biotechnology ETF (IBB)
  • SPDR S&P Biotech ETF (XBI)

Competitive Landscape

The biotech ETF landscape is competitive, including leveraged and non-leveraged funds. LABU's advantage is its high leverage, appealing to aggressive traders. However, this comes with higher risk and the disadvantage of potential significant losses due to the leveraged nature of the fund, especially compared to non-leveraged competitors like IBB and XBI.

Financial Performance

Historical Performance: Historical performance is highly volatile, with significant gains during bull markets but substantial losses during downturns. Due to its leveraged nature, it should not be considered for long-term investing.

Benchmark Comparison: Due to the 3x leverage, LABU's daily performance aims to be 3x of the S&P Biotechnology Select Industry Index, but tracking errors and compounding effects can lead to significant deviations over longer periods.

Expense Ratio: 0.95

Liquidity

Average Trading Volume

LABU has high average trading volume, indicating good liquidity.

Bid-Ask Spread

The bid-ask spread is generally tight, reflecting the ETF's high liquidity.

Market Dynamics

Market Environment Factors

Economic indicators, healthcare policy changes, FDA approvals, and overall market sentiment towards the biotech sector significantly influence LABU's performance.

Growth Trajectory

LABU's growth is tied to investor appetite for risk and the biotech sector's performance. Strategy and holdings remain aligned with its leveraged index-tracking objective, but are rebalanced daily.

Moat and Competitive Advantages

Competitive Edge

LABU's competitive advantage lies in its 3x leverage, providing amplified exposure to the biotech sector's daily performance. This makes it attractive to day traders and those seeking short-term gains. However, this high leverage also introduces a high level of risk that is amplified by the biotech sector, which is inherently volatile. Direxion's expertise in managing leveraged ETFs contributes to its competitive position.

Risk Analysis

Volatility

LABU exhibits extremely high volatility due to its 3x leverage and the inherent volatility of the biotech sector. Expect frequent and potentially large price swings.

Market Risk

LABU is highly susceptible to market risk, especially downturns in the biotech sector. The leveraged nature amplifies both gains and losses, potentially leading to significant capital erosion, particularly due to daily compounding effects.

Investor Profile

Ideal Investor Profile

LABU is suitable for sophisticated, short-term traders with a high risk tolerance and a deep understanding of leveraged ETFs and the biotech sector. It is not suitable for long-term investors.

Market Risk

LABU is designed for active traders seeking short-term gains, not for long-term investors or passive index followers. The leveraged nature makes it unsuitable for buy-and-hold strategies.

Summary

Direxion Daily S&P Biotech Bull 3X Shares (LABU) provides leveraged exposure to the biotech sector, magnifying daily gains and losses. It is a high-risk, high-reward investment vehicle designed for short-term trading strategies. The ETF's performance is heavily influenced by biotech sector trends and overall market sentiment. Due to the inherent risks associated with leveraged ETFs and the biotech industry, LABU is only suitable for experienced traders with a high risk tolerance. Investors should carefully consider the potential for significant losses before investing in LABU.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Direxion Funds Website
  • ETF.com
  • Yahoo Finance

Disclaimers:

The data provided is for informational purposes only and should not be considered financial advice. Past performance is not indicative of future results. Leveraged ETFs are high-risk investments and may not be suitable for all investors.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Direxion Daily S&P Biotech Bull 3X Shares

Exchange NYSE ARCA
Headquaters -
IPO Launch date -
CEO -
Sector -
Industry -
Full time employees -
Website
Full time employees -
Website

The fund, under normal circumstances, invests at least 80% of its net assets in financial instruments, such as swap agreements, securities of the index, and ETFs that track the index, that, in combination, provide 3X daily leveraged exposure to the index, consistent with the fund's investment objective. The index is designed to measure the performance of the biotechnology sub-industry based on the Global Industry Classification Standards (GICS). The fund is non-diversified.